Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized...

Area of Science:

• Medical research
• Clinical trials
• Thrombosis

Background:

• Deep venous thrombosis (DVT) incidence remains high in surgical patients despite enoxaparin prophylaxis.
• Previous studies suggested a link between enoxaparin's R time change (ΔR) on TEG and reduced DVT rates.

Purpose of the Study:

• To investigate if thromboelastography (TEG)-guided enoxaparin dosing reduces DVT rates in general surgery and trauma patients.
• To evaluate the impact of TEG-guided dosing on enoxaparin's efficacy and patient outcomes.

Main Methods:

• Prospective, randomized controlled trial at a Level 1 trauma center.
• Patients received either standard enoxaparin dosing or TEG-guided dosing aiming for a ΔR of 1-2 minutes.
• Measured demographic data, DVT/pulmonary embolism rates, antithrombin III (AT-III) activity, and anti-Xa levels.

Main Results:

• No significant difference in DVT rates between standard (16%) and TEG-guided (14%) groups.
• TEG-guided dosing resulted in higher enoxaparin doses and anti-Xa levels but did not alter TEG ΔR.
• A high prevalence of AT-III deficiency (67%) was observed in the study cohort.

Conclusions:

• TEG-adjusted enoxaparin dosing increased anti-Xa activity but failed to decrease DVT rates.
• High AT-III deficiency may limit the effectiveness of enoxaparin optimization.
• Future DVT prevention may require strategies independent of or directly enhancing the antithrombin pathway.